Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation

20 Jun 2008

Abstract excerpt

Cutaneous mastocytosis (CM) in children is a usually benign skin disorder caused by mast cell proliferation. Progressive disease leading to systemic involvement and fatal outcomes has been described. C-kit receptor mutations have been identified as causative for CM, some of which potentially respond to imatinib treatment as described for patients with systemic mastocytosis. We report successful therapy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Eosinophilic Disorders and Syndromes
Share to Mast cells and histamine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18567837
DOI: 10.1182/blood-2008-03-147785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutationPMID 18567837Read ↗

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literatureSemantic proximity Read ↗

Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.Semantic proximity Read ↗

Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant.Semantic proximity Read ↗

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.Semantic proximity Read ↗

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.Semantic proximity Read ↗

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.Semantic proximity Read ↗

Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study.Semantic proximity Read ↗

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibSemantic proximity Read ↗

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.Semantic proximity Read ↗

Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.